Howard Burris, MD, FACP, FASCO, president of clinical operations and chief medical officer of Sarah Cannon Research Institute, discusses how oncology biosimilars will impact financial toxicity.
I don’t think there will be the drastic cost reduction that some people are hoping for that we see with some drugs, because it is complicated to make some of the biologics, to make the monoclonal antibodies. But I do think that will create some price pressure, that’ll create some alternatives.
On the flip side, I think one thing that often happens in that setting, it does motivate scientists, pharma, biotech, to come up with even better therapies. So hopefully, it’ll be a win-win solution: decreasing financial toxicity on one hand, and leading to even better therapies on the other.